🇺🇸 FDA
Pipeline program

89Zr-TLX250 PET/CT

TLX250CDx-CP-002

Phase 3 small_molecule active

Quick answer

89Zr-TLX250 PET/CT for Clear Cell Renal Cell Carcinoma is a Phase 3 program (small_molecule) at Telix Pharmaceuticals Ltd with 1 ClinicalTrials.gov record(s).

Program details

Company
Telix Pharmaceuticals Ltd
Indication
Clear Cell Renal Cell Carcinoma
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials